Stay updated on RX-5902 in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the RX-5902 in Triple Negative Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check76 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about a Phase 2 study of RX-5902 for treating triple negative breast cancer, and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference27%
Stay in the know with updates to RX-5902 in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.